A Single and Repeat Dosing Study of the Safety, Drug Exposure, and Clinical Activity of R-3750 in Patients with Mild to Moderate Ulcerative Colitis
Latest Information Update: 05 Feb 2026
At a glance
- Drugs R 3750 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; First in man; Proof of concept
Most Recent Events
- 29 Jan 2026 Planned End Date changed from 1 Oct 2025 to 1 Oct 2026.
- 29 Jan 2026 Planned primary completion date changed from 1 Sep 2025 to 1 Jul 2026.
- 07 Apr 2025 According to the Rise Therapeutics media release, first clinical results from the completed dose escalation segment will be presented at the Digestive Disease Week (DDW) Conference in San Diego May 3-6.